 |
|
Multiple-Attack Efficacy and Tolerability of Sumatriptan Nasal Spray in the Treatment of Migraine
Seymour Diamond, MD;
Arthur Elkind, MD;
R. Terry Jackson, MD;
Robert Ryan, MD;
Sandy DeBussey;
Mahnaz Asgharnejad, PharmD
Arch Fam Med. 1998;7:234-240.
Objective Sumatriptan hemisulfate nasal spray may provide a useful therapeutic option for patients with migraine who find injectable medications inconvenient or uncomfortable and for patients whose migraine-associated nausea and vomiting preclude the use of oral medication. This study was the first US trial to evaluate the effects of sumatriptan nasal spray administered for multiple migraine attacks.
Design/Interventions Sumatriptan nasal spray (5, 10, or 20 mg) was administered via a 1-shot nasal applicator into either nostril for up to 3 migraine attacks occurring over 6 months in a randomized, double-blind, parallel-group, placebo-controlled study.
Setting Fifty-six outpatient clinical centers in the United States.
Patients A total of 1086 men and women diagnosed with migraine with or without aura per International Headache Society criteria.
Main Outcome Measures Percentage of patients with headache relief (moderate or severe predose pain reduced to mild or none); percentage of patients with no or mild (vs moderate or severe) clinical disability; percentage of patients with nausea, vomiting, photophobia, or phonophobia; adverse events; clinical laboratory test results.
Results Across attacks, headache relief in the 20-, 10-, and 5-mg drug and placebo groups was experienced 120 minutes postdose by 60%, 54%, 44%, and 32% of patients, respectively (P<.05 for each sumatriptan nasal spray group vs placebo, for the 10-mg vs 5-mg drug group, and for the 20-mg vs 5-mg drug group). Two thirds of the 20-mg patients treating 3 attacks experienced relief at 2 hours postdose for at least 2 of 3 attacks. Clinical disability scores at 120 minutes in the 20-, 10-, and 5-mg drug and placebo groups reflected no or mild impairment in 70%, 67%, 57%, and 50% of patients, respectively (P<.05 for the 10- or 20-mg drug group vs placebo group, and for the 20-mg vs 5-mg drug group). Similar efficacy rates were observed for nausea, photophobia, and phonophobia. For all parameters, individual-attack efficacy rates did not differ from across-attack rates. The incidence of adverse events was not dose related. The most frequently reported adverse event in the active treatment groups was taste disturbance (bad, bitter, or unpleasant).
Conclusions Sumatriptan hemisulfate nasal spray (5, 10, or 20 mg) is effective and well tolerated in the treatment of multiple migraine attacks. The 20-mg dose was associated with the highest efficacy rates across the greatest number of parameters.
From the Diamond Headache Clinic, Chicago, Ill (Dr Diamond); Elkind Headache Center, Mt Vernon, NY (Dr Elkind); Department of General Internal Medicine, University of Mississippi, Jackson (Dr Jackson); Ryan Headache Center, St Louis, Mo (Dr Ryan); and Glaxo Wellcome Inc, Research Triangle Park, NC (Ms DeBussey and Dr Asgharnejad).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study
Djupesland et al.
Cephalalgia 2010;30:933-942.
ABSTRACT
| FULL TEXT
Open label study of intranasal sumatriptan (Imigran) for footballer's headache
McCrory et al.
Br. J. Sports. Med. 2005;39:552-554.
ABSTRACT
| FULL TEXT
Clinical applications of new therapeutic deliveries in migraine
Dahlof
Neurology 2003;61:S31-34.
ABSTRACT
| FULL TEXT
Patient Treatment Preferences and the 5-HT1B/1D Agonists
Ryan
Arch Intern Med 2001;161:2545-2553.
ABSTRACT
| FULL TEXT
The Sumatriptan Nasal Spray: A Review of Clinical Trials
Rapoport
Cephalalgia 2001;21:13-15.
FULL TEXT
Treatment of Migraine Attacks with Intranasal Alniditan: An Open Study
Diener et al.
Cephalalgia 2001;21:140-144.
ABSTRACT
| FULL TEXT
A Randomized, Double-Blind, Placebo-Controlled Study of Sumatriptan Nasal Spray in the Treatment of Acute Migraine in Adolescents
Winner et al.
Pediatrics 2000;106:989-997.
ABSTRACT
| FULL TEXT
Sumatriptan Nasal Spray in the Acute Treatment of Migraine: A Review of Clinical Studies
Dahlof
Cephalalgia 1999;19:769-778.
ABSTRACT
Diagnosis of Migraine
Diamond
Arch Fam Med 1999;8:198-198.
FULL TEXT
|
